Lisa H. Butterfield, Ph.D., is a Professor of Medicine, Surgery and Immunology at the University of Pittsburgh and Director of the Immunologic Monitoring and Cellular Products Laboratory (IMCPL) at the University of Pittsburgh Cancer Institute (UPCI). She obtained her PhD in Biology at UCLA, followed by postdoctoral fellowships in Cellular Immunology and Cancer Gene Therapy. She is the President of the Society of ImmunoTherapy of Cancer (SITC), and on the Immune Biomarkers Task Force Steering Committee. Dr. Butterfield also serves as Director of the ECOG-ACRIN (US) National Clinical Trials Network Immunology Reference Laboratory, as well as Melanoma Committee Lab Liaison. She investigates immunotherapy and cancer vaccines for hepatocellular cancer and for melanoma involving peptides, dendritic cells and adenoviruses and effector responses to tumor antigens. She has been involved in 4 melanoma and 3 HCC early stage clinical trials testing vaccines, being the IND Sponsor for two of them. She has published over 100 peer reviewed papers and mentored many students and postdocs. As Associate Director (2005-2010) and Director of the UPCI IMCPL (2010-present), she oversees the cellular product production and immunologic monitoring for multiple trials and multiple types of products involving dendritic cells, NK cells, T cells and others. The IMCPL is cGMP and cGTP, and maintains FACT, CAP, CLIA, State of PA and other certifications and a current FDA Master File.